文献速递免疫规划

用重组VLP混合库免疫鉴定疫苗候选表位

Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs.
PubMed 文献 · Vaccine · 2026-08-13

研究以促炎细胞因子IL-17A为模型抗原,构建展示覆盖其133个氨基酸的全部线性10肽的MS2噬菌体病毒样颗粒(VLP)文库并免疫小鼠,用产生的抗IL-17A抗体从文库中筛选单个重组VLP;筛选出的VLP可在小鼠中诱生抗IL-17A抗体,将合成肽偶联至Qβ VLP平台可提高抗体水平。该工作提出一种无需既有抗体、不依赖计算预测的抗原非依赖性表位发现与疫苗开发方法。

要点

  • 以IL-17A为模型,用展示全部线性10肽的MS2 VLP文库免疫小鼠筛选表位
  • 筛选出的VLP可诱生抗IL-17A抗体,偶联Qβ VLP可提升抗体水平
  • 该策略不依赖既有抗体或计算预测,可用于表征不足蛋白的表位发现

核心结论

  • 用复杂重组VLP混合库免疫可借助免疫系统揭示候选蛋白中能诱生靶向抗体应答的区域,实现抗原非依赖性表位发现与疫苗开发。

研究设计与样本

  • 以IL-17A(133个氨基酸的促炎细胞因子)为模型抗原,构建展示全部线性10肽的MS2噬菌体VLP文库,免疫小鼠后用产生的抗IL-17A抗体筛选单个重组VLP并在小鼠中测试其诱生抗体能力。

主要发现

  • 筛选出的重组VLP能够在小鼠中诱生抗IL-17A抗体应答;将代表所选表位的合成肽偶联至Qβ VLP平台后抗体水平可提高。

临床怎么用

  • 为表位聚焦疫苗设计提供不依赖既有抗体和计算预测的候选表位筛选思路,可先以模型抗原验证流程再拓展至其他靶点。

局限性

  • 原文为摘要,未报告小鼠数量、抗体滴度数值、统计学比较及所选表位具体序列等信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying the regions of a protein that can be readily translated into an effective vaccine remains a major challenge in epitope-focused vaccine design, especially when a protein is poorly characterized. Here, we describe an immune-driven strategy for epitope identification which uses the immune system to reveal regions within a candidate protein capable of eliciting targeted antibody responses. Using IL-17A, a pro-inflammatory cytokine, as a model antigen, we engineered a comprehensive library of MS2 bacteriophage virus-like particles (VLPs) displaying peptides representing every possible linear 10-amino acid peptide spanning the 133-amino acid protein. We then used the library to immunize mice, with the hypothesis that a subset of the IL-17A VLP mixture would elicit anti-IL-17A antibody responses. The IL-17A-reactive antibodies elicited by this complex vaccine were then used to select individual recombinant VLPs from the starting library, which were then tested for their ability to elicit anti-IL-17A antibodies in mice. Selected recombinant VLPs were able to elicit anti-IL-17A antibody responses, and antibody levels could be improved by conjugating synthetic peptides representing the selected epitopes to another bacteriophage platform (Qβ VLPs). Overall, this work describes a new method for antigen-agnostic epitope discovery and vaccine development that does not require pre-existing antibodies or rely on computational approaches to identify potential epitopes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nepal Y, Wondra G, Jones DT, et al. Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs. Vaccine. 2026. PMID: 42594642. doi:10.1016/j.vaccine.2026.129027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。